Condition: Stroke, Acute Ischemic · Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
A multicenter, prospective, open-label, blinded endpoint, randomized controlled trial aiming at evaluating the efficacy and safety of intra-arterial recombinant human tissue plasminogen activator (rt-PA) after successful recanalization of acute large vessel occlusion in the anterior circulation by mechanical thrombectomy in improving the 90-day functional outcome.
This description comes directly from the study's public registry record.
Xinguang Yang · 86-20-81332619 · yangxinguang0926@163.com
Xiongjun He · 075523360593 · drxjhe@163.com
Always discuss trial participation with your own doctor first.
| Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University | Guangzhou, Guangdong, China | Recruiting |
| Shenzhen Hospital of Southern Medical University | Shenzhen, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05856851